II. Indications
- Ventricular Arrhythmia
- Other Antiarrhythmics are preferred
III. Contraindications
- Structural heart disease (prior Myocardial Infarction, Systolic Dysfunction)
IV. Mechanism
- Class Ib Antiarrhythmic Drug
- Decreases automaticity at AV Node and ectopic focil
- Increases refractory period in His Bundle, Purkinje Fibers, ventricle and accessory pathways
V. Precautions
- Other Antiarrhythmics are preferred (consult cardiology)
- Consider dose adjustment in severe liver disease
- Proarrhythmic
- Higher mortality in non-life threatening ventricular Arrhythmia and structural heart disease
VI. Dosing
- Start: 200 mg every 8 hours with food
- Titrate dose to effect
- May convert to twice daily dosing when effective dose identified
- Maximum
- Three times daily: 1200 mg/day (400 mg/dose)
- Twice daily: 900 mg/day (450 mg/dose)
-
Renal Dosing for eGFR <10 ml/min
- Decrease to 50 to 75% of typical dose
VII. Safety
- Avoid in Lactation
- Pregnancy Category C
VIII. Adverse Effects
- Proarrhythmic
- Hepatotoxicity
- Neurotoxicity
- Seizures
IX. Drug Interactions
- Mexiletine may increase levels of other medications
- Other medications may effect drug levels of Mexiletine
X. Resources
XI. References
- Olson (2020) Clinical Pharmacology, Medmaster Miami, p. 74-5
- van der Ree (2022) Europace 24(11):1809-23 +PMID: 36036670 [PubMed]
Images: Related links to external sites (from Bing)
Related Studies
mexiletine (on 12/21/2022 at Medicaid.Gov Survey of pharmacy drug pricing) | ||
MEXILETINE 150 MG CAPSULE | Generic | $0.43 each |
MEXILETINE 200 MG CAPSULE | Generic | $0.70 each |
MEXILETINE 250 MG CAPSULE | Generic | $0.92 each |
Ontology: Mexiletine (C0025887)
Definition (NCI) | A local anesthetic and antiarrhythmic (Class IB) agent structurally related to lidocaine. Mexiletine exerts its antiarrhythmic effect by inhibiting the inward sodium current in cardiac cells, thereby reducing the rate of rise of the cardiac action potential (phase 0) and decreases automaticity in the Purkinje fibers. This slows nerve impulses in the heart and stabilizes the heartbeat. Mexiletine's anesthetic activity is due to its ability to block sodium influx in peripheral nerves, thereby reducing the rate and intensity of pain impulses reaching the central nervous system. |
Definition (CSP) | antiarrhythmia agent pharmacologically similar to lidocaine. |
Definition (MSH) | Antiarrhythmic agent pharmacologically similar to LIDOCAINE. It may have some anticonvulsant properties. |
Concepts | Pharmacologic Substance (T121) , Organic Chemical (T109) |
MSH | D008801 |
SnomedCT | 372909002, 96298001 |
LNC | LP16205-4, MTHU004263 |
English | Mexiletine, 2-Propanamine, 1-(2,6-dimethylphenoxy)-, mexiletine, mexiletine (medication), Mexiletine [Chemical/Ingredient], Mexiletinum, 1-Methyl-2-(2,6-xylyloxy)ethylamine, MEXILETINE, Mexiletine (product), Mexiletine (substance) |
Swedish | Mexiletin |
Czech | mexiletin |
Finnish | Meksiletiini |
Russian | MEKSILETIN, KO 1173, МЕКСИЛЕТИН |
Japanese | メトレキシン, メキシチール, メキシレチン塩酸塩, 塩酸メキシレチン, メキシレチン, メレート |
Polish | Meksyletyna |
Spanish | mexiletina (producto), mexiletina (sustancia), mexiletina, Mexiletine |
French | Méxilétine |
German | Mexiletin |
Italian | Mexiletina |
Portuguese | Mexiletina |